Aldeyra Therapeutics, Inc.

Stephen Gitu Machatha

David J Clark

Todd Brady

Jonathan James Loughrey

Susan Macdonald

Dean Eliott

Tomasz Stryjewski

Hannah Ruth McLachlan

Gregor Sneddon

Charles Montgomery

Pramod Sarpotdar

Scott Young

Osama Suleiman

Amanda Buist

Steven Krausert

Eden Fucci

Kate Wittering

Lise Lund Kjems

Adam Brockman

The present invention relates to methods for synthesizing compounds, and to intermediates thereto, useful for treating various conditions in which aldehyde toxicity is implicated in the pathogenesis.

Process for preparation of aldehyde scavenger and intermediates

The present invention relates to pharmaceutical compositions and unit dosage forms comprising a quinoline compound, or a pharmaceutically acceptable salt thereof, which are useful for treatment of a disease, disorder, or condition such as inflammatory diseases, respiratory diseases, organ diseases, viral infections, and sequelae and associated conditions such as acute respiratory distress syndrome.

Pharmaceutical formulations and uses thereof

The present invention relates to free-base and salt forms, and compositions thereof of small molecule therapeutics acting as a scavenger for toxic aldehydes. The present invention further relates to use of the free-base and salt forms, and compositions thereof for treating diseases, disorders, or conditions in which aldehyde toxicity is implicated in their pathogenesis.

Polymorphic compounds and uses thereof

The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.

Ophthalmic formulations of methotrexate

The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions in which aldehyde toxicity is implicated in the pathogenesis by the administration of small molecule therapeutics acting as a scavenger for toxic aldehydes.

The present disclosure provides compositions of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), uveitis, macular edema, and uveitic macular edema.

Methotrexate treatment methods

The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating a disease or disorder such as allergic conjunctivitis.

Ophthalmic formulations and uses thereof

The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease.

Formulations for treatment of dry eye disease

The present disclosure provides methods of treating eye allergies and allergic conjunctivitis with cyclodextrin. Ophthalmic compositions of cyclodextrin for topical administration are also provided.

Treatment of allergic eye conditions with cyclodextrins

The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions, in which aldehyde toxicity is implicated in the pathogenesis, by the administration of small molecule therapeutics acting as a scavenger for toxic aldehydes.

Growing community of inventors

Wilmington, MA, United States of America

Stephen Gitu Machatha